NIH. Sexual and gender minority terms and definitions. 2022. Available from: https://www.edi.nih.gov/people/sep/lgbti/safezone/terminology [Last accessed: September 21, 2022].
2.
IHS. Indian Health Services: Two-Spirit. Indian Health Service. 2022. Available from: https://www.ihs.gov/lgbt/health/twospirit [Last accessed: September 21, 2022].
3.
HermanJL, FloresAR, O'NeillKK. How many adults and youth identify as transgender in the United States? 2022. Available from: https://williamsinstitute.law.ucla.edu/publications/trans-adults-united-states/ [Last accessed: October 22, 2022].
4.
JamesSE, HermanJL, RankinS, et al. The Report of the 2015 U.S. Transgender Survey. 2016. Available from: https://transequality.org/sites/default/files/docs/usts/USTS-Full-Report-Dec17.pdf [Last accessed: October 22, 2022].
5.
PharrJR, BatraK. Propensity score analysis assessing the burden of non-communicable diseases among the transgender population in the United States using the behavioral risk factor surveillance system (2017–2019). Healthcare (Basel), 2021; 9(6); doi: 10.3390/healthcare9060696
6.
FoundationHRC. Fatal violence against the transgender and gender non-conforming community in 2022. 2022. Available from: https://www.hrc.org/resources/fatal-violence-against-the-transgender-and-gender-non-conforming-community-in-2022 [Last accessed: September 28, 2022].
7.
BecasenJS, DenardCL, MullinsMM, et al.Estimating the prevalence of HIV and sexual behaviors among the US transgender population: A systematic review and meta-analysis, 2006–2017. Am J Public Health, 2019; 109(1):e1–e8.
8.
CDC. HIV Infection, Risk, Prevention, and Testing Behaviors Among Transgender Women—National HIV Behavioral Surveillance, 7 U.S. Cities, 2019–2020 (HIV Surveillance Special Report 27, Issue). 2021. Available from: https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html [Last accessed: October 20, 2022].
9.
LemonsA, BeerL, FinlaysonT, et al.Characteristics of HIV-positive transgender men receiving medical care: United States, 2009–2014. Am J Public Health, 2018; 108(1):128–130; doi: 10.2105/AJPH.2017.304153
10.
FDA. FDA approves first drug for reducing the risk of sexually acquired HIV infection. 2012. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310542.htm [Last accessed October22, 2022].
11.
KuhnsLM, ReisnerSL, MimiagaMJ, et al.Correlates of PrEP indication in a multi-site cohort of young HIV-uninfected transgender women. AIDS Behav, 2016; 20(7):1470–1477; doi: 10.1007/s10461-015-1182-z
12.
RaelCT, MartinezM, GiguereR, et al.Barriers and facilitators to oral PrEP use among transgender women in New York City. AIDS Behav, 2018; 22(11):3627–3636; doi: 10.1007/s10461-018-2102-9
13.
DeutschMB, GliddenDV, SeveliusJ, et al.HIV pre-exposure prophylaxis in transgender women: A subgroup analysis of the iPrEx trial. Lancet HIV, 2015; 2(12):e512–e519; doi: 10.1016/s2352-3018(15)00206-4
14.
EscuderoDJ, KerrT, OperarioD, et al.Inclusion of trans women in pre-exposure prophylaxis trials: A review. AIDS Care, 2015; 27(5):637–641; doi: 10.1080/09540121.2014.986051
15.
Viiv. Apretude Prescribing Information. 2022. Available from: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Vocabria/pdf/VOCABRIA-PI-PIL.PDF [Last accessed: October 22, 2022].
16.
HoffmanH. Long-acting injectable form of HIV prevention outperforms daily pill inNIH study. 2020. Available from: https://www.nih.gov/news-events/news-releases/long-acting-injectable-form-hiv-prevention-outperforms-daily-pill-nih-study [Last accessed: October 20, 2022].
17.
LandovitzR, DonnellD, ClementM, et al. HPTN-083 final results: Pre-exposure prophylaxis containing long-acting injectable cabotegravir is safe and highly effective for cisgender men and transgender women who have sex with men AIDS 2020, Virtual. 2020. Available from: https://www.hptn.org/sites/default/files/inline-files/HPTN083_PrimaryAIDS2020_Landovitz-Final_web.pdf [Last accessed: October 22, 2022].
18.
BakkoM, KattariSK. Differential access to transgender inclusive insurance and healthcare in the United States: Challenges to health across the life course. J Aging Soc Policy, 2021; 33(1):67–81; doi: 10.1080/08959420.2019.1632681
19.
BlosnichJR, MarsiglioMC, DichterME, et al.(2017). Impact of social determinants of health on medical conditions among transgender veterans. Am J Prev Med, 2017; 52(4):491–498; doi: 10.1016/j.amepre.2016.12.019
20.
HillBJ, CrosbyR, BourisA, et al.Exploring transgender legal name change as a potential structural intervention for mitigating social determinants of health among transgender women of color. Sex Res Social Policy, 2018; 15(1):25–33; doi: 10.1007/s13178-017-0289-6
21.
KlemmerCL, ArayasirikulS, RaymondHF. Transphobia-based violence, depression, and anxiety in transgender women: The role of body satisfaction. J Interpers Violence, 2021; 36(5–6):2633–2655.
22.
LernerJE, RoblesG. Perceived barriers and facilitators to health care utilization in the United States for transgender people: A review of recent literature. J Health Care Poor Underserved, 2017; 28(1):127–152; doi: 10.1353/hpu.2017.0014
23.
ShiehE, MarzinkeMA, FuchsEJ, et al.Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men. J Int AIDS Soc, 2019; 22(11):e25405; doi: 10.1002/jia2.25405
